Medical

Diagnosis, treatment options, hormone therapy and surgical procedures — an overview of the medical side of transition.

Medical transition includes hormone therapy, various surgical procedures and — for minors — possibly puberty blockers. Many of these interventions are major and partly or wholly irreversible. Loss of fertility, permanent changes to voice, body and sexual function, and lifelong dependence on medication are among the consequences that must be fully on the table before such a pathway is started. Full information about this is not a "transphobic" obstacle, but a basic requirement for informed consent.

The Dutch care model is historically based on the so-called Dutch Protocol: puberty blockers from around age 12, cross-sex hormones from around age 16, surgery generally from age 18. This model has been firmly contested internationally since the Cass Review (2024) and earlier revisions in Sweden, Finland, Norway and Denmark. The systematic literature reviews carried out in those countries conclude that the scientific basis for early medical intervention is "remarkably weak".

This section covers every step in the medical pathway — from diagnosis and waiting times, through hormones and their side effects, to mastectomy, vaginoplasty, phalloplasty, facial surgery and voice training. With each part, both the procedure and the risks and regret experiences known from detransition research are described. Good medical care requires both sides of the story.

What a diagnosis means

'Gender dysphoria' is the clinical term for a persistent experience of incongruence between body and gender identity, with clinically significant distress. In the DSM-5 it has its own chapter; in the ICD-11 it has been moved to 'gender variation' under sexual health, no longer under mental disorders. That shift is contested: critics argue that depathologisation simplifies access to care without the evidence base necessarily having changed.

Comorbidity

In young people with gender dysphoria, comorbidity is substantial: autism spectrum disorders, depression, anxiety disorders, trauma, eating disorders. Whether the dysphoria is a primary experience, a consequence of underlying problems, or an interaction differs from individual to individual. Affirmative models treat the dysphoria first; cautious models treat the comorbidity first.

Risks of untreated dysphoria

Untreated, clinically significant dysphoria can cause severe suffering: depression, social isolation, suicidality. Advocates of affirmative care point to those risks as an argument for rapid treatment. Critics point out that suicidality figures in comparative studies are often poorly supported and that the implicit blackmail ('treat quickly or the child will die') makes parental deliberation impossible.

Risks of medical transition

Hormone therapy has systemic effects: cardiovascular (increased risk with oestrogen), bone density (reduced with puberty blockers), fertility (often permanently reduced), psychological (mood effects). Surgical procedures each have their own complication profile — mastectomy is reversible in silhouette but not in function; vaginoplasty and phalloplasty have substantial long-term complication rates.

Irreversibility

Puberty blockers between ages eleven and sixteen affect bone density and possibly brain development — contested quantitatively, acknowledged qualitatively. Cross-sex hormones cause irreversible voice and body changes after a few years. Surgery is by definition irreversible. The chain — blockers, hormones, surgery — is therefore step by step less reversible, while the care model has been based since the original Dutch Protocol on the idea of 'time to decide'.

Detransition

How many people detransition is unknown. The figures in official reports (1-2%) rest on clinics that rarely follow up with patients after they leave. Independent estimates (Littman, Vandenbussche) come out substantially higher, with percentages between 6-25% depending on follow-up duration and definition. The absence of a Dutch detrans register is structural.

The Dutch care model under pressure

The Dutch Protocol has been re-evaluated internationally and substantially restricted in Scandinavia, the UK and France. The Dutch care chain still largely operates according to the original model, with referral numbers that have exploded and waiting times that run into years. Whether the model can withstand the combination of a substantially changed patient population and an internationally changed assessment of the evidence is an open question.

What patient and family need to know

Full information includes: the nature of each procedure, the cumulative irreversibility, the limited evidence for long-term outcomes, the existence of detransition as a real outcome, and the absence of adequate care for those who want to go back. Only with that information can informed consent be meaningful.